Zoetis Inc. $ZTS Shares Sold by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,875,126 shares of the company’s stock after selling 43,385 shares during the period. Zoetis makes up 1.7% of Brown Brothers Harriman & Co.’s holdings, making the stock its 15th biggest holding. Brown Brothers Harriman & Co. owned 0.43% of Zoetis worth $274,368,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Norges Bank purchased a new stake in shares of Zoetis during the 2nd quarter valued at approximately $809,491,000. Diamond Hill Capital Management Inc. acquired a new stake in Zoetis during the third quarter worth $394,010,000. Arrowstreet Capital Limited Partnership raised its position in Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after purchasing an additional 1,227,085 shares during the period. Corient Private Wealth LLC lifted its stake in shares of Zoetis by 85.9% in the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after purchasing an additional 1,191,840 shares during the last quarter. Finally, First Trust Advisors LP grew its holdings in shares of Zoetis by 342.1% during the 3rd quarter. First Trust Advisors LP now owns 1,485,459 shares of the company’s stock worth $217,352,000 after purchasing an additional 1,149,467 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several research analyst reports. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a report on Thursday, December 18th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Bank of America lifted their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Finally, Barclays initiated coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Stock Up 0.1%

ZTS stock opened at $115.62 on Friday. The company’s 50 day moving average price is $125.34 and its 200 day moving average price is $131.91. The firm has a market capitalization of $48.81 billion, a price-to-earnings ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95. Zoetis Inc. has a fifty-two week low of $114.47 and a fifty-two week high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.